Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/54900
Citations
Scopus Web of Science® Altmetric
?
?
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVink, R.en
dc.contributor.authorCook, N.en
dc.contributor.authorVan Den Heuvel, C.en
dc.date.issued2009en
dc.identifier.citationMagnesium Research, 2009; 22(3):158S-162Sen
dc.identifier.issn0953-1424en
dc.identifier.issn1952-4021en
dc.identifier.urihttp://hdl.handle.net/2440/54900-
dc.description.abstractWhile brain free magnesium levels have been shown to decline in a number of acute and chronic brain pathologies, the mechanisms of such decline and the potential for magnesium administration as a therapeutic intervention are still unclear. In acute brain injury, magnesium therapy has failed in recent clinical trials of trauma, presumably because of an intact blood brain barrier at the time of administration reducing central penetration. Under such conditions, magnesium’s peripheral effects on cardiovascular parameters may dominate over the central, and potentially neuroprotective, effects of the compound. In contrast, magnesium has been demonstrated to be beneficial in lacunar strokes, albeit that recent animal studies indicate that this effect is without any significant reduction of lesion size. Postnatal magnesium has also been shown to improve neurological outcome in term neonates with perinatal asphyxia, although this may be limited to cases of mild to moderate brain injury; no effect is observed following severe brain injury. Prenatal magnesium has been reported to be beneficial for outcome in very preterm infants, although this may only be at low doses. Combination therapies are also showing promise in experimental studies, with combined magnesium and mild hypothermia as well as magnesium and polyethylene glycol proving effective in ischemic stroke and in spinal cord injury, respectively. With respect to chronic brain injury, recent results indicate that magnesium deficient mice are susceptible to developing Parkinson’s disease, which is consistent with earlier findings that magnesium deficiency over a number of generations is associated with the development of Parkinson’s disease. The latter was associated with the appearance of variants of the TRPM channels. Our recent studies have shown that Parkinson’s disease is associated with reduced TRPM2 and TRPM7 channel mRNA expression. Taken together, a more complete picture is emerging of the role of magnesium in brain injury, its therapeutic potential as well the mechanisms associated with its decline.en
dc.description.statementofresponsibilityRobert Vink, Naomi L Cook, Corinna van den Heuvelen
dc.language.isoenen
dc.publisherJohn Libbey & Co Ltden
dc.subjectmagnesium, neurotrauma, ischemia, hypoxia, neurodegeneration, Parkinson’s diseaseen
dc.titleMagnesium in acute and chronic brain injury: an updateen
dc.typeJournal articleen
dc.identifier.rmid0020092408en
dc.identifier.doi10.1684/mrh.2009.0175en
dc.identifier.pubid37737-
pubs.library.collectionPathology publicationsen
pubs.verification-statusVerifieden
pubs.publication-statusPublisheden
dc.identifier.orcidVink, R. [0000-0002-4885-0667]en
dc.identifier.orcidCook, N. [0000-0002-1830-2432]en
dc.identifier.orcidVan Den Heuvel, C. [0000-0001-7264-4655]en
Appears in Collections:Pathology publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.